NervGen Pharma(NGEN)
$1.85-0.07 (-3.91%)
NGEN
NervGen Pharma financials statements
$1.85
At close:-0.07 (-3.91%)
Want to see NGEN full AI Analyst Report?
NervGen Pharma (NGEN) Ratios
143 Followers
NervGen Pharma Ratios
NGEN's free cash flow for Q3 2026 was C$-12.81M. For the 2026 fiscal year, NGEN's free cash flow was increased by C$0.00 and operating cash flow was C$-12.81M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.16 | 1.12 | 0.83 | 2.27 | 16.16 |
| Quick Ratio | 1.16 | 1.12 | 0.83 | 2.27 | 16.16 |
| Cash Ratio | 1.12 | 1.02 | 0.77 | 2.20 | 15.70 |
| Solvency Ratio | -2.23 | -1.41 | -1.46 | -1.73 | -11.69 |
| Operating Cash Flow Ratio | -0.99 | -1.00 | -0.75 | -1.74 | -7.67 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -173.20 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | C$ 3.07M | C$ 2.10M | C$ -2.73M | C$ 12.73M | C$ 16.34M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.04 | -0.10 | 0.02 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.04 | -0.11 | 0.02 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 6.68 | 7.56 | -6.59 | 1.77 | 1.06 |
| Debt Service Coverage Ratio | 0.00 | -246.03 | 0.00 | -33.96 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -44.35 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Net Debt to EBITDA | 3.90 | 0.72 | 0.65 | 1.10 | 1.33 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 87.38% | 99.33% |
| EBT Per EBIT | 175.91% | 96.29% | 125.91% | 90.79% | 98.91% |
| Return on Assets (ROA) | -190.08% | -123.19% | -169.10% | -75.84% | -70.64% |
| Return on Equity (ROE) | -1268.86% | -931.69% | 1114.03% | -134.51% | -75.17% |
| Return on Capital Employed (ROCE) | -721.31% | -964.50% | 933.90% | -167.10% | -76.50% |
| Return on Invested Capital (ROIC) | -719.57% | -929.53% | 981.10% | -145.09% | -75.99% |
| Return on Tangible Assets | -193.49% | -126.21% | -176.03% | -77.23% | -72.56% |
| Earnings Yield | -7.94% | -5.80% | -13.98% | -21.49% | -11.79% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.26 | 0.06 | 0.12 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -1385.46 | -6347.61 | -3018.80 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 1385.46 | 6347.61 | 3018.80 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.27 | -0.25 | -0.19 | -0.34 | -0.21 |
| Free Cash Flow Per Share | -0.27 | -0.25 | -0.19 | -0.34 | -0.21 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -79.88 | -842.65 | -183.41 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -79.88 | -842.65 | -183.41 |
| Operating Cash Flow Coverage Ratio | -2329.93 | -159.48 | -57.28 | -62.74 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -3.51% | -4.07% | -7.14% | -21.14% | -7.75% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.60 | -17.06 | -7.15 | -4.65 | -8.48 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 159.85 | 160.55 | -79.68 | 6.26 | 6.38 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -28.50 | -24.56 | -14.00 | -4.73 | -12.90 |
| Price-to-Operating Cash Flow Ratio | -28.50 | -24.56 | -14.17 | -4.74 | -12.97 |
| Price-to-Earnings Growth (PEG) Ratio | -0.18 | 6.31 | -0.61 | -0.74 | 0.99 |
| Enterprise Value Multiple | -94.43 | -16.58 | -8.43 | -3.09 | -7.07 |
| Enterprise Value | 533.72M | 396.25M | 148.62M | 62.07M | 90.33M |
| EV to EBITDA | -94.43 | -16.58 | -8.43 | -3.09 | -7.07 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -27.37 | -23.54 | -12.99 | -3.49 | -10.86 |
| EV to Operating Cash Flow | -27.37 | -23.54 | -13.16 | -3.49 | -10.92 |
| Tangible Book Value Per Share | 0.04 | 0.03 | -0.04 | 0.25 | 0.42 |
| Shareholders’ Equity Per Share | 0.05 | 0.04 | -0.03 | 0.26 | 0.43 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.13 | 0.01 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.61 | -0.36 | -0.38 | -0.34 | -0.32 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.87 | 0.99 |
| Interest Burden | 7.73 | 1.00 | 1.26 | 0.90 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.44 | 0.70 | 0.50 | 0.86 | 0.65 |
Currency in CAD

